Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man

Prostate

Volumn 70, Issue 15, 2010, Pages 1628-1635

  Inoue, Takamitsu ^a,b   Zakikhani, Mahvash ^a   David, Stéphanie ^a   Algire, Carolyn ^a,b   Blouin, Marie José ^a   Pollak, Michael ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Castration; IGF 1; Insulin; Metabolic syndrome; Mouse; Prostate cancer

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; LEPTIN; SOMATOMEDIN C; ANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; C57BL 6 MOUSE; CALORIC INTAKE; CASTRATION; COMPARATIVE TOXICOLOGY; CONTROLLED STUDY; ENERGY CONSUMPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; SHAM PROCEDURE; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; METABOLISM; MOUSE MUTANT; NEOPLASM; NUDE MOUSE; PHYSIOLOGY; PROSTATE TUMOR; RANDOMIZATION;

ADIPONECTIN; ANDROGENS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DISEASE MODELS, ANIMAL; ENERGY INTAKE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOM ALLOCATION;

EID: 77958195769     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21198     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin 2009; 59: 225 -249.
2. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68 -80.
3. Huggins C, Hodges CV,. Studies on prostatic cancer 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293 -297.
4. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL,. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002; 95: 2136 -2144.
5. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S,. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979 -3983.
6. Smith MR, Lee H, Fallon MA, Nathan DM,. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71: 318 -322.
7. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE, Wake RW,. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007; 100: 1060 -1065.
8. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448 -4456.
9. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39 -46.
10. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF,. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452 -3458.
11. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ,. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008; 28: 1511 -1522.
12. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305 -1308.
13. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS,. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581 -588.
14. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C,. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195 -201.
15. Hsing AW, Sakoda LC, Chua S Jr., Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: s843 -s857.
16. Mistry T, Digby JE, Desai KM, Randeva HS,. Obesity and prostate cancer: A role for adipokines. Eur Urol 2007; 52: 46 -53.
17. Baillargeon J, Rose DP,. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006; 28: 737 -745.
18. Mallah KN, Diblasio CJ, Rhee AC, Scardino PT, Kattan MW,. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer 2005; 103: 2030 -2034.
19. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M,. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008; 9: 1039 -1047.
20. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915 -928.
21. Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ,. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J Natl Cancer Inst 2001; 93: 783 -789.
22. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG,. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 2002; 87: 726 -728.
23. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG,. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002; 50: 1 -3.
24. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M,. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563 -566.
25. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H,. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: Evidence from 96 studies. Eur J Hum Genet 2009; 17: 1668 -1675.
26. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E,. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099 -1106.
27. Cox M, Gleave M, Zakikhani M, Bell R, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M,. Insulin receptor expression by human prostate cancers. Prostate 2009; 69: 33 -40.
28. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M,. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99: 1793 -1800.
29. Basaria S,. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. J Androl 2008; 29: 534 -539.
30. Smith MR,. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742 -745.
31. Robertson ID,. The influence of diet and other factors on owner-perceived obesity in privately owned cats from metropolitan Perth, Western Australia. Prev Vet Med 1999; 40: 75 -85.
32. Fettman MJ, Stanton CA, Banks LL, Hamar DW, Johnson DE, Hegstad RL, Johnston S,. Effects of neutering on bodyweight, metabolic rate and glucose tolerance of domestic cats. Res Vet Sci 1997; 62: 131 -136.
33. Kanchuk ML, Backus RC, Calvert CC, Morris JG, Rogers QR,. Neutering induces changes in food intake, body weight, plasma insulin and leptin concentrations in normal and lipoprotein lipase-deficient male cats. J Nutr 2002; 132: 1730S -1732S.
34. Kanchuk ML, Backus RC, Calvert CC, Morris JG, Rogers QR,. Weight gain in gonadectomized normal and lipoprotein lipase-deficient male domestic cats results from increased food intake and not decreased energy expenditure. J Nutr 2003; 133: 1866 -1874.
35. McGreevy PD, Thomson PC, Pride C, Fawcett A, Grassi T, Jones B,. Prevalence of obesity in dogs examined by Australian veterinary practices and the risk factors involved. Vet Rec 2005; 156: 695 -702.
36. Crane SW,. Occurrence and management of obesity in companion animals. J Small Anim Pract 1991; 32: 275 -282.
37. Rowe RW,. Effect of castration on muscle growth in the mouse. J Exp Zool 1968; 169: 59 -64.
38. Engel P,. Body and muscle growth in normal and castrate albino mice. Endocrinology 1941; 29: 852 -853.
39. Kochakian CD, Tillotson C, Endahl GL,. Castration and the growth of muscles in the rat. Endocrinology 1956; 58: 226 -231.
40. Christoffersen B, Raun K, Svendsen O, Fledelius C, Golozoubova V,. Evalution of the castrated male Sprague-Dawley rat as a model of the metabolic syndrome and type 2 diabetes. Int J Obes (Lond) 2006; 30: 1288 -1297.
41. Meinhardt UJ, Ho KK,. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 2006; 65: 413 -422.
42. Kadowaki T, Yamauchi T,. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439 -451.
43. Bullen JW Jr, Bluher S, Kelesidis T, Mantzoros CS,. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2007; 292: E1079 -E1086.
44. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S,. Prostate cancer and adiponectin. Urology 2005; 65: 1168 -1172.
45. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J,. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010; 56: 34 -43.
46. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E,. Serum adiponectin levels in hypogonadal males: Influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004; 60: 500 -507.
47. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y,. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734 -2741.
48. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS,. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073 -18080.
49. Teske E, Naan EC, van Dijk EM, Van Garderen E, Schalken JA,. Canine prostate carcinoma: Epidemiological evidence of an increased risk in castrated dogs. Mol Cell Endocrinol 2002; 197: 251 -255.